Continuation of the collaborative islet transplantation registry (citr)

Active Cooperative Agreement Awarded Last action

Award ID
U01DK133709
Recipient
Awarding agency
Obligated
$4,785,806

Award facts

Completion date 86% complete
Place of performance
Rockville, MD 20850, USA

Award details come from USAspending.gov.

Description

As the agency reported it.

Abstract
This application, in response to RFA-DK-21-013, describes a comprehensive data and statistical coordinating center (dscc) for the collaborative islet transplant registry (citr) for 2022-2027. Continuing from 2017-2021 as the citr-dscc, emmes continues to collaborate with the niddk program office, the oversight committee, and the citr investigators to support the established citr registry. The registry includes allogeneic and autologous pancreatic islet transplantation, as well as any other beta cell replacement therapies that should be followed for efficacy and safety in the resolution of refractory glycemic lability marked by severe hypoglycemic episodes in persons with type 1 diabetes or lacking pancreatic islets for any reason including therapeutic pancreatectomy or any loss of islet cell function. For more details, please see the specific aims section.

Transactions

Action Obligated Date
Amendment $633,968
Amendment $646,310
Amendment $0
Amendment $0
Amendment $314,470
Amendment $314,470
Amendment $703,698
Amendment $703,698
Amendment $734,596
Original award $734,596

Quick answers

Who received award U01DK133709?

U01DK133709 was awarded to The Emmes Company, LLC by National Institute of Diabetes and Digestive and Kidney Diseases (National Institutes of Health) on September 15, 2022.

How much is award U01DK133709 worth?

$4,785,806 has been obligated on U01DK133709.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award
Try for free Login